Lys106

Site Information
RDMLLANkVPAAARA SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3933635

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 )
Disease tissue studied:	leukemia ( 5 ) , testicular cancer ( 4 )
Relevant cell line - cell type - tissue:	'brain, embryonic' ( 6 ) , brain ( 1 ) , ES-J1 (stem) ( 3 ) , F9 (testicular) ( 4 ) , heart ( 1 ) , kidney ( 1 ) , liver ( 1 ) , pooled tissues ( 1 ) , PYS-2 (epithelial) ( 2 ) , RAW 264.7 (macrophage) ( 5 )

References
1	Wagner SA, et al. (2012) Proteomic analyses reveal divergent ubiquitylation site patterns in murine tissues. Mol Cell Proteomics 11, 1578-85 22790023 Curated Info
2	Zhou J (2010) CST Curation Set: 9134; Year: 2010; Biosample/Treatment: cell line, PY2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
3	Zhou J (2010) CST Curation Set: 9129; Year: 2010; Biosample/Treatment: cell line, ES J1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
4	Zhou J (2010) CST Curation Set: 9130; Year: 2010; Biosample/Treatment: cell line, F9/untreated; Disease: testicular cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
5	Possemato A (2009) CST Curation Set: 6916; Year: 2009; Biosample/Treatment: cell line, RAW 264.7/untreated; Disease: leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
6	Guo A (2007) CST Curation Set: 3116; Year: 2007; Biosample/Treatment: tissue, brain, embryonic/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info